Inhibitors of endopeptidase and angiotensin-converting enzyme lead to an amplification of the morphological changes and an upregulation of the substance P system in a muscle overuse model
© Song et al.; licensee BioMed Central Ltd. 2014
Received: 30 May 2013
Accepted: 4 April 2014
Published: 11 April 2014
We have previously observed, in studies on an experimental overuse model, that the tachykinin system may be involved in the processes of muscle inflammation (myositis) and other muscle tissue alterations. To further evaluate the significance of tachykinins in these processes, we have used inhibitors of neutral endopeptidase (NEP) and angiotensin-converting enzyme (ACE), substances which are known to terminate the activity of various endogenously produced substances, including tachykinins.
Injections of inhibitors of NEP and ACE, as well as the tachykinin substance P (SP), were given locally outside the tendon of the triceps surae muscle of rabbits subjected to marked overuse of this muscle. A control group was given NaCl injections. Evaluations were made at 1 week, a timepoint of overuse when only mild inflammation and limited changes in the muscle structure are noted in animals not treated with inhibitors. Both the soleus and gastrocnemius muscles were examined morphologically and with immunohistochemistry and enzyme immunoassay (EIA).
A pronounced inflammation (myositis) and changes in the muscle fiber morphology, including muscle fiber necrosis, occurred in the overused muscles of animals given NEP and ACE inhibitors. The morphological changes were clearly more prominent than for animals subjected to overuse and NaCl injections (NaCl group). A marked SP-like expression, as well as a marked expression of the neurokinin-1 receptor (NK-1R) was found in the affected muscle tissue in response to injections of NEP and ACE inhibitors. The concentration of SP in the muscles was also higher than that for the NaCl group.
The observations show that the local injections of NEP and ACE inhibitors led to marked SP-like and NK-1R immunoreactions, increased SP concentrations, and an amplification of the morphological changes in the tissue. The injections of the inhibitors thus led to a more marked myositis process and an upregulation of the SP system. Endogenously produced substances, out of which the tachykinins conform to one substance family, may play a role in mediating effects in the tissue in a muscle that is subjected to pronounced overuse.
KeywordsMuscle Exercise Overuse Myositis Tachykinin Substance P
A pronounced muscle inflammation (myositis) and a derangement of the structure of muscle tissue occur in inflammatory myopathies [1, 2]. Muscle inflammation and alterations of muscle structure also occur in response to muscle overuse after heavy exercise and in situations with repetitive strain injury . We have recently studied the development of myositis, as well as muscle tissue derangement, in response to muscle overuse in the triceps surae muscle of the rabbit . Using this overuse model, we have observed that there is an upregulation in the expression of tachykinin [substance P (SP)] and the SP-preferred receptor [the neurokinin-1 receptor (NK-1R)] in muscle areas showing inflammation/tissue derangement [5, 6]. All these features were clearly noticeable after 3-6 weeks of experimental overuse and to a small extent after an experimental period of 1 week. The observations suggest that tachykinins are involved in the myositis/derangement processes.
SP is the most well-known peptide in the tachykinin family. It is found in the C fiber population of primary afferent neurons and is released from their central and peripheral endings [7, 8]. SP is also present in non-neuronal cells such as white blood cells . SP has marked pro-inflammatory properties [10–12], as evidenced by participation in neurogenic inflammation [13, 14] and in the processes of extravasation and accumulation of inflammatory cells . Increased SP effects are considered to lead to an up-regulation of NK-1R expression, consistent with an activation of the NK-1 R [16, 17].
Exogenous administration of SP via injections or via topical treatment has been tested experimentally and has been shown to have effects in a large number of inflammatory/destructive events, as well as in repair and wound-healing processes [18–20]. These include repair processes in models of Achilles tendon rupture [21, 22]. Local administration of SP outside the Achilles tendon has been found to accelerate hypercellularity and angiogenesis within this tendon in an experimental tendinopathy-like situation .
The activity of tachykinins, such as SP, and certain other peptide mediators is terminated by enzymatic degradation and by receptor inactivation. The most important enzymes are neutral endopeptidase (NEP), which degrades SP in the extracellular space [24–26], and angiotensin-converting enzyme (ACE) . Local injections of SP and/or endopeptidase inhibitor are reported to have a booster effect on endogenous SP production . The present study was undertaken in order to further determine the role for tachykinin involvement in muscle derangement and inflammation processes. We have used the rabbit overuse model to study this. We performed the combined exercise/electrical stimulation experiment for 1 week and in order to obtain pronounced effects of endogenously produced substances, we gave local treatments with ACE- and NEP-inhibitors. SP was also given. It was hypothetized that the exogenous treatments with ACE- and NEP-inhibitors, as well as SP, would lead to pronounced activation of the NK-1R and an increased inflammation process and tissue derangement.
In the experiments, female New Zealand white rabbits with a weight of approximately 4 kg (age ranging from 6 to 9 months) were utilized. In total, the investigation included evaluations of 16 animals. All the animals were subjected to an exercise protocol leading to marked overuse of the triceps surae muscle. The muscle overuse was combined with injection treatment (see below).
The animals were exposed to an exercise procedure that was performed according to previously described procedures , with some modifications [4–6, 23]. The rabbits were kept under anaesthesia, induced by i.m. injections of diazepam (5 mg/ml; 0.2 ml/kg) and fentanylfluanison (0.2-0.3 ml/kg), throughout the experiment. Fentanylfluanison (0.1 ml/kg) was injected each 30-45 min during the experiment in order to maintain the anaesthesia. The experiments lasted for 2 hours. For analgesia, buprenorphine (0.01-0.05 mg/kg) was given s.c. after each experimental session. The experiment was repeated every second day for one week (4 exercise sessions in total).
In order to achieve passive repetitive flexions and extensions of the right ankle joint, an apparatus (“kicking machine”) was used. A pneumatic piston attached to the foot produced the movements. An active contraction was furthermore induced by electrical stimulation via surface electrodes (Pediatric electrode 40 426A, Hewlett Packard, Andover, MA, USA) placed 2 cm apart over the triceps surae muscle of the right leg. This active contraction occurred during the plantar flexion phase. The stimulation was synchronized with the plantar flexion movement of the piston by a microswitch, which trigged the stimulator unit (Disa stimulator Type 14E, Disa Elektronik A/S, Herlev, Denmark). An impulse of 0.2 ms duration was delivered 85 ms after the initiation of the plantar flexion at an amplitude of 35-50 V. The movement frequency was 150 movements per minute. The left leg was not attached to the kicking machine and the pelvis was strapped down. In-between the experimental periods, the animals were kept in ordinary cages allowing good freedom of movement. For further details about the apparatus and the exercise protocol, see [4–6, 23].
Injections were given in the loose connective tissue outside the Achilles tendon, i.e. in the paratenon region, of the right leg. The injections were given directly after each of the exercise regimens. The substances injected were Captopril (C) (c4042; Sigma), DL-Thiorphan (Th) (T 6031; Sigma), substance P (SP) (S6883; Sigma) and NaCl. Captopril is an angiotensin-converting enzyme inhibitor (ACE inhibitor) and DL-Thiorphan inhibits the activity of neutral endopeptidase (NEP). NEP is also called enkephalinase and neprilysin or common acute lymphoblastic leukemia antigen or CD10 .
Injections were performed as follows: a) Substance P (10-8 μmol/ml) and Captopril (30 μmol/kg) both in distilled water (volume: 1 ml) + Dl-Thiorphan (500 μg/ml; 0.02 ml) (5 animals), b) Captopril (30 μmol/kg, dissolved in distilled water, volume 1 ml) + DL-Thiorphan (500 μg/ml, 0.02 ml) (6 animals), c) NaCl (volume: 1 ml) (5 animals). The groups are further referred to as the SP + C + Th group, the C + Th group and the NaCl group.
Collection of muscle samples, fixation and sectioning
The animals were sacrificed, using an overdose of Pentobarbital, the day after the last exercise. The triceps surae muscles were dissected out. Directly thereafter the muscle samples were transported on ice to the laboratory. The distal parts of the soleus and gastrocnemius muscles (5-8 × 10 mm) were dissected out. Specimens from all samples were collected and processed in three ways: Immersion fixed, directly embedded/frozen or directly frozen in liquid nitrogen. For all types of specimens, specimens from all the various muscles were obtained. Thus, for both the soleus and gastrocnemius muscles, 5-6 specimens were generated for each experimental condition.
For fixation, specimens were fixed by immersion overnight at 4°C in an ice-cold solution of 4% formaldehyde in 0.1 M phosphate buffer (pH 7.0). These specimens were thereafter thoroughly washed in Tyrode’s solution containing 10% sucrose at 4°C overnight, mounted on thin cardboard in OCT embedding medium (Miles Laboratories, Naperville, Ill.), and frozen in propane chilled with liquid nitrogen. Other specimens were, as described above, directly embedded and frozen. Both types of specimens were stored at -80°C and from both types, series of 7-8 μm thin sections were cut using a cryostat. The sections were mounted on slides precoated with chrome-alum gelatine and were then processed for morphology (chemically unfixed samples) or immunohistochemistry and morphology (chemically fixed samples). Other specimens weighing approximately 30 mg were directly frozen in liquid nitrogen. They were further used for EIA analyses.
From one of the experimental groups (the SP + C + Th group) specimens, conforming to all three types of specimens as described above, were collected from both the right and left legs.
Processing for morphology (haematoxylin & eosin)
Sections in the series were stained in Harris Haematoxylin solution for 2 min. They were then rinsed in distilled water, dipped in 0.1% acetic acid for a few seconds, followed by washing in running water. Counterstaining was achieved by immersion in eosin for 1 min. The sections were dehydrated in ethanol and mounted in Permount.
Morphological semiquantitative evaluations
Evaluations with respect to the magnitude of morphological changes were made. The evaluations were based on the haematoxylin & eosin (H&E) stainings. The evaluations were made blinded.
The degree of inflammatory infiltrates in the tissue and the degree of presence of abnormal connective tissue areas, necrotic muscle fibers and variations in muscle fiber sizes as well as the degree of occurrence of internal nuclei were all assessed. An overall estimation for all these parameters was performed. The evaluations included an overall estimation of the entire sections from both the chemically unfixed and fixed specimens of each muscle.
The following pattern of scoring was used: 0 = no changes; morphology resembling that seen in normal muscle tissue, 1 = mild degree of changes, 2 = moderate degree of changes, 3 = marked changes, 4 = very marked changes. The scoring was relative, i.e. the magnitude of changes in one muscle was related to those in others. The mean value for scores for the different groups was then calculated. The significance level was set at the 0.05 level. The scoring is a simplified scoring method in relation to the one used in our previous morphological study on the effects of 1,3 and 6 weeks of experiment . Based on the experience we obtained from that study, we consider that the scoring procedures that were presently used are reliable. Thus, the degree of occurrence of the different abnormal features analyzed parallelled each other.
Staining procedures for demonstration of substance P (SP) and NK-1R
Two antibodies for staining for demonstration of SP were used. One of the SP antibodies and the NK-1 R antibody were goat polyclonal antibodies (see below). The staining procedures for these antibodies conformed to those previously described [5, 6]. This included the use of 5% normal donkey serum (code no: 017-000-121, Jackson ImmunoResearch Lab. Inc., PA) as normal serum and FITC-conjugated AffiniPure donkey antigoat IgG (705-095-147; Jackson ImmunoResearch Lab Inc, dilution 1:100) as secondary antiserum. Mounting was performed in Vectashield Mounting Medium (H-1000) (Vector Laboratories, Burlingame, CA) and examination was carried out in a Zeiss Axioscope 2 plus microscope equipped with an Olympus DP70 digital camera.
Staining using a monoclonal SP antibody was also performed. In this case, an initial incubation with Triton X-100 was done, followed by incubation in 5% normal donkey serum and incubation with the primary antibody, diluted in PBS with BSA, in a humid environment. Incubation was performed for 60 min at 37°C. Another incubation in normal donkey serum followed, after which the sections were incubated with secondary antiserum. As secondary antiserum, tetramethylrhodamine isothiocyanate (TRITC)-conjugated AffiniPure donkey anti-rat IgG (712-025-150) (Jackson ImmunoResearch, PA), diluted 1:40 in PBS supplemented with 0.1% BSA, was used. Incubation with secondary antiserum proceded for 30 min at 37°C. The procedures for mounting and examination were as described above.
As an alternative procedure for demonstration of SP and NK-1R immunoreactions, sections were initially pretreated with acid potassium permanganate for 2 min, a procedure found to enhance specific immunofluorescence reactions . After this pretreatment, the procedures described above followed. Both procedures (with or without acid potassium permanganate treatment) gave in principle similar results. There were, however, some differences in staining intensities and levels of background reactions, why it was useful to analyse sections by using both types of procedures.
Stainings for demonstration of desmin and CD31
Immunostaining for desmin was used in order to verify the occurrence of muscle fiber necrosis since it is well-known that necrotic muscle fibers show no or negligible desmin immunoreactivity [31, 32]. CD31 is a well-known marker of endothelia of blood vessels.
The CD31 staining was performed using visualization with FITC-conjugated donkey anti-mouse IgG (715-095-15) (Jackson ImmunoResearch), dilution used 1:100, and as normal serum, normal donkey serum with PBS in BSA was utilized. For the evaluation of desmin reaction patterns, double staining desmin/NK-1R was made. FITC-conjugated AffiniPure donkey anti-goat IgG (705-095-147) was used as secondary antibody for visualization of NK-1R and 5% normal donkey serum in PBS was used as normal serum. Concerning desmin immunodetection, rabbit anti-mouse immunolobulins/TRITC (R0276) (Dako, Denmark) was used as secondary antiserum, 1:40 dilution being used, and 5% normal rabbit serum in PBS with BSA as normal serum. Mounting was made in Vectashield Mounting Medium (H-1000).
Antibodies and control stainings
An affinity purified goat polyclonal SP antibody was utlized. It was obtained from Santa Cruz Biotechnology (code: sc-14104) and was used at a dilution of 1:25-1:50. This antibody is raised against a peptide mapping within an internal region of preprotachykinin 1 of human origin and is recommended for detection of mature SP and all isoforms of the protachykinin 1 precursor of various species [mouse, rat and human origin]. According to “Human Protein Reference Database” and “BLAST-Basic Local Alignment Search Tool”, the protein sequence of rabbit protachykinin 1 shows at least 85% identity with human protachykinin 1.
A rat monoclonal SP antibody was also used. It was obtained from Biogenesis, Poole, UK (code: 8450-0505). It was used at a dilution of 1:50-1:100. The antibody is reported to recognize the COOH terminal end of SP and has been previously used for immunohistochemical detection of SP in experimental animals and man [5, 33].
Control stainings included the use of SP blocking substance (code: sc14104P; Santa Cruz) (20-50 μg/ml antiserum) and SP peptide (full length SP peptide; S6883; Sigma) (50 μg/ml antiserum). Ordinary stainings with the SP antisera were performed in parallel. Other control stainings conformed to stainings when the primary antibodies were excluded (buffer instead of the antibody).
A NK-1R antibody produced in goats was used (code: sc-5220, Santa Cruz). It is an affinity purified polyclonal antibody raised against a peptide mapping within an internal region of NK-1R of human origin. It was used at a dilution of 1:50-1:100 in 0.1% PBS. It has been previously used in studies on immunoexpression patterns in rabbit muscle tissue . Control stainings included the use of NK-1R blocking substance (sc-5220P) (50 μg/ml antiserum). Ordinary stainings for NK-1R were made in parallel. As was the case concerning stainings for SP, other control stainings conformed to stainings when the primary antibody was excluded.
CD31 and desmin antibodies
Mouse monoclonal antibodies against CD31 and desmin were used. The CD31 antibody was obtained from Dako, Glostrup, Denmark (code: M0823) and was used at a dilution of 1:100. It is a marker of the endothelial cells of blood vessel walls and has previously been used with reliable results in our laboratory . The desmin antibody was also obtained from Dako, Glostrup, Denmark (code: Ab D33) and was utilized at a dilution of 1:100. It is by the supplier reported to be specific for desmin and to not show reactivity with other types of intermediate filaments. This antibody has been evaluated in previous studies .
Processing for EIA
After being frozen in liquid nitrogen (see above), the samples were homogenised, by mechanical homogenization using a Precellys 24 tissue homogenizer (Bertin Technologies, Saint Quentin en Yvelines, Cedex, France), in a 100 mM Tris-HCl buffer, pH 7.0, containing 1 M NaCl, 2% BSA, 4 mM EDTA, 0.2% Triton X-100 (pH 7.0), 0.02% Na-azide and the protease inhibitors Pepstatin A (0.1 μg/ml), Aprotinin (5 μg/ml), Antipain (0.5 μg/ml), Benzamidin (167 μg/ml) and PMSF (5.2 μg/ml). All the protease inhibitors were purchased from Sigma, Germany. Tissue and buffer were mixed in a 1:20 ratio. The procedure was performed on ice. Directly after the homogenisation procedure, the tissue samples were centrifuged in +4°C, 13 000 g, for 15 min. The supernatant was then transferred to a new Eppendorf tube and stored at -80°C.
The concentration of SP in the muscle samples was evaluated using commercially available enzyme immunoassay SP kits (Phoenix Pharmaceuticals, Burlingame, CA, USA). The sequence of the peptide detected conforms to the full-length of SP. 100% cross-reactivity is also reported for SP 2-11 – SP 5-11. Less than 0.01% cross-reactivity is reported for SP 7-11, neuropeptide K and neurokinin A and 0% for neurokinin B. The assays were performed in accordance with the instructions from the manufacturer. In order to obtain comparable results between different plates, reference samples were included in the various analyses. The levels of SP were normalized to the weights of the tissue samples, i.e. the values are expressed as pg/mg tissue.
All data are expressed as mean and standard deviations (SD) are given. A one way ANOVA in combination with post hoc comparisons by use of Least Square Difference (LSD) was used for analysis of differences between the different groups. The paired t test was used for the evaluation of possible differencees in SP concentration between the experimental and non-experimental sides (concerning SP + C + Th group). The normality for the data for each group was examined and the distribution was found to be normal or approximately normal. All the statistical analysis was performed by software SPSS (PASW Statistics 20). A p-value < 0.05 was considered to be significant.
The study protocol was approved by the local ethical committee at Umeå University (A34/07, A95/07). A licensed breeder had bred all the animals for the sole purpose of being used in animal experiments. All efforts were made to minimize animal suffering.
When compared with the muscles of the NaCl group, it was noted that the morphological changes were clearly more pronounced for the muscles of the C + Th and SP + C + Th groups (c.f. Figure 1A). Morphological alterations such as occurrence of necrotic fibers were only sometimes observed in the NaCl group (Figure 1A).
Mean values of the scoring of morphological changes and the mean values of SP concentations as measured by EIA in the soleus (SOL) and gastrocnemius (GM) muscles for the NaCI, SP + C + Th and C + Th groups are shown
Scores for morphology
SP concentration (pg/mg)
NaCI (n = 5)
1.5 ± 1.1
1.2 ± 0.4
240 ± 50
353 ± 147
SP + C + Th (exp) (n = 5)
2.3 ± 0.8
2.0 ± 1.3
351 ± 75 (363)
511 ± 134#
SP + C + Th (non-exp) (n = 5)
3.0 ± 1.1
2.1 ± 0.7
295 ± 67
450 ± 55
C + Th (n = 6)
3.8 ± 0.6#
2.2 ± 0.5
509 ± 160#▲□ (422)
531 ± 104#
C + Th and SP + C + Th groups
The two SP antibodies used were directed against different epitopes (see Materials & Methods). As will be described below, there was a difference in the reaction pattern for the two antibodies. We further on use the terminology “SP-like” immunoreactivity to describe the reactions obtained using the two antibodies. The terminology “tachykinin-like” was used in a previous study .
Marked SP-like immunoreactions were observed in myositis areas and areas adjacent to these in the C + Th group and both sides of the SP + C + Th group. The magnitude of immunoreactions was especially high in the C + Th group.
Specific immunoreactions were obtained for nerve fibers and white blood cells using both the polyclonal and monoclonal antibodies, whilst specific immunoreactions in the blood vessel walls were only obtained with the polyclonal antiserum. The polyclonal antibody thus depicts a broader tachykinin spectrum, the antibody detecting all isoforms of the protachykinin 1 precursor.
Immunoexpression of NK-1 R
Very marked NK-1R immunoreactions were noted for the C + Th group and for both sides of the SP + C + Th group. As was the case concerning the location of the marked SP-like immunoreactions described above, the NK-1R immunoreactions were especially observed for myositis areas and areas that were close to these. NK-1R immunoreactions occurred for white blood cells of the inflammatory infiltrates (Figure 3C) and were also detected in nerve fascicles (Figure 4D). NK-1R immunoreactions were also detected in necrotic muscle fibers (Figure 5C) and blood vessel walls in myositis areas (not shown).
Immunoexpression of desmin and CD31
It was clearly obvious that the frequently occurring muscle fibers, which based on the appearance after staining for H&E were interpreted to represent necrotic muscle fibers, were indeed desmin-negative (Figure 5A). Normally-appearing muscle fibers were, on the other hand, showing desmin immunoreaction (Figure 5A).
There were numerous blood vessels showing CD31-immunoreaction in the areas composed of loose connective tissue containing numerous white blood cells, i.e. myositis areas (Figure 2A).
SP-like and NK-1R immunoreactions were also detected in white blood cells, blood vessel walls and nerve fascicles in the muscle tissue of the NaCl group, but these reactions were of clearly lower degree and frequency than those seen for the C + Th and SP + C + Th groups. A parallel observation was, as commented on above, that the morphological changes were also less pronounced in the NaCl group (c.f. Figure 1A).
The SP concentration was significantly higher in the C + Th group compared with the NaCI group (509 pg/mg vs. 240 pg/mg, p < 0.001), and there was also a significantly higher mean value in the C + Th group than in the SP + C + Th group (experimental side) as well (509 pg/mg vs. 351 pg/mg, p < 0.02) and similarly, there was a difference between the C + Th group and the non-experimental side of the SP + C + Th group (509 pg/mg vs. 295 pg/mg, p = 0.001). There was a tendency of an increase in SP concentration in the SP + C + Th group (concerning both experimental and non-experimental sides) as compared with the NaCI group. The tendency was most pronounced for the experimental side. Nevertheless, the difference was not statistically significant. No significant difference was found between experimental and non-experimental sides for the SP + C + Th group (p = 0.178). All values are presented in Table 1.
The SP concentration was significantly higher in the C + Th group as compared with the NaCI group (531 pg/mg vs. 353 pg/mg, p = 0.017, respectively) (Table 1). It was also significantly higher in the SP + C + Th group (experimental side) as compared with the NaCI group (511 pg/mg vs. 353 pg/mg, p = 0.039, respectively). No significant difference was found between experimental and non-experimental sides for the SP + C + Th group (p = 0.316).
The study shows that the local injections with NEP and ACE inhibitors provoked the myositis/muscle derangement processes that occur in response to the overuse. It was evident that the muscles of animals that had been given the local inhibitory substances showed a more pronounced tissue derangement than those treated with NaCl. The increase was most clearly seen for the soleus muscle in the C + Th group. The present study also shows that the local injections with C + Th and to some extent also the injections with SP + C + Th led to more marked NK-1R and SP-like immunoreactions in the myositis areas and in the adjacent areas. There were higher SP concentrations in the muscle tissue of these two groups than in that of the NaCl group. It was very obvious that the morphological alterations and the upregulations in expressions of SP/NK-1R were much more noticeable for the C + Th and SP + C + Th groups than for animals subjected to the overuse for 1w using our model and when no injections were given [4–6].
There was a tendency for a more pronounced tissue derangement/inflammation in the C + Th group as compared to the SP + C + Th group. There was a significantly higher SP concentration in the C + Th group compared to the SP + C + Th group concerning the soleus muscle. One explanation to the occurrence of the differences between the two groups can be the fact that exogenously given tachykinin, such as SP, is short-lived, why the major effects we see are those of the ACE and NEP inhibitors. For example, it was previously shown that the plasma extravasation elicited by topical application of SP onto rabbit joint capsule is short-lived, the high extravasation initially seen not being observed 24 h after the experiment . Endogenous SP is also known to be stable in human plasma in vitro whilst added exogenous SP disappears from it rapidly [35, 36]. Another explanation to the differences between the C + Th and SP + C + Th groups may be that it can not be excluded that the exogenously given SP to a certain extent leads to a down-regulation of the endogenous SP production.
Marked SP-like and NK-1R immunoreactions and increased SP concentrations
The use of the polyclonal SP antibody showed that there were immunoreactions in blood vessel walls. Reactions at this location were not seen by the use of the monoclonal SP antibody. The polyclonal SP antibody is directed against all isoforms of the protachykinin 1 precursor, why it is possible that not only SP but also other tachykinins are involved in blood vessel function in the muscle tissue.
The marked SP-like/NK-1R immunoreactions that were seen in myositis areas and areas adjacent to these included immunoreactions for the frequently occurring white blood cells and, as seen by use of the polyclonal antibody, the walls of blood vessels. SP-like/NK-1R immunoreactions occurred within large nerve fascicles and frequent SP-like immunoreactive fine varicose profiles were also seen. The study also shows that the SP concentration was increased due to the inhibitor treatments, especially in the C + Th group.
These observations suggest that the NK-1R was activated and that a boostering of SP occurred due to the local inhibitor injections. The latter suggestion is in accordance with findings by Steyaert and colloborators in their studies on SP treatment for ruptured rat Achilles tendons showing that exogenously administered SP had a booster effect on endogenous SP production .
Possible SP effects
It is well described that local SP treatments can have inflammatory-mediating and destructive effects [10, 12, 19]. The NK-1R can on the whole have a significant role in the damaging processes during the occurrence of injury and inflammation .
Despite the well-known fact that tachykinins have pro-inflammatory effects [10, 12], the role for tachykinins like SP in healing effects should also be considered. SP is known to have trophic and healing effects [19, 38], including in the initial stages of Achilles tendon healing in the rat . Rats with high residual SP levels after capsaicin-induced neuropathy showed more improvements than those with low levels in the healing of the rat Achilles tendon .
It is likely that other substances, in addition to tachykinins, are also involved in the inflammatory and reorganization processes that occur in the muscle tissue. Accordingly, it is reported that although SP can evoke an inflammatory respose in the knee joint, this effect is unlikely to be a function on its own . It should here be emphasized that various peptides in the tachykinin family can bind to the NK-1R . We have also ourselves noted that there is an enhanced expression of TNF-alpha in the myositis process in the model used in this study and it was concluded that tachykinin (SP) can be involved in its upregulation . Further studies will reveal which other substances that are also involved. It should here be emphasized that NEP not only hydrolyzes tachykinins but also enkephalins [24, 42] and that ACE degrades not only tachykinins but also bradykinin . ACE is also reported to degrade endothelin-1 and possibly also CGRP . This means that the C + Th treatments not only leads to increased SP levels in the tissue.
To summarize, it is presumable that tachykinins such as SP, as is suggested for certain other situations , can have double-edged effects in the processes of myositis/muscle derangement, tachykinins being involved in both pro-inflammatory and reparative processes. In accordance with this concept, we noted in our previous study on NK-1R expression patterns in myositis for animals excercised/electrically stimulated for 3-6 weeks and for which animals no injections were given , an occurrence of NK-1R expression in both necrotic and regenerating muscle fibers. Further studies will reveal the relationships between the pro-inflammatory and healing effects.
In the study, muscle samples in the group treated with SP + C + Th were analyzed concerning both the experimental side and the contralateral side. It was found that there were tendencies for more marked alterations of the muscle tissue and an increase in SP concentration for both sides, as compared to the NaCl group, the SP increase being especially obvious for the gastrocnemius muscle. This shows that unilateral exercise/electrical stimulation parallelled by injection of local inflammatory-modulating substances leads to effects also contralaterally. Similarly, we have noted that morphological changes  and occurrence of upregulations in tachykinin (SP-like)  and NK-1 R  expressions are seen bilaterally in response to the prolonged (3-6 weeks) exercise/electrical stimulation protocol without injections being given. Our interpretation has been that neural mechanisms are likely to be involved as the morphological changes (the myositis and muscle derangement) occurred focally and not generally and as influences on the structure of nerve fascicles could be observed. Nevertheless, further electrophysiological and CNS studies are needed in order to prove this.
Previous studies have shown that there is an inflammatory component in the muscle/tendon affection in response to overuse . In studies on flexor digitorum tendons using a rat model of repetitive strain injury it was shown that there was an exposure-dependent increase in SP immunoexpression in the peritendon tissue . The present study gives new information on the involvement of SP within muscle tissue in a condition of marked muscle overuse.
In conclusion, it is here shown that the local injections of C + Th markedly amplified the structural changes in the muscle tissue and lead to increased SP-like and NK-1R immunoexpressions in the myositis areas and increased SP concentrations in the tissue. To a certain extent, the SP + C + Th treatment led to smilar changes. The changes are likely to be attributed to increased effects of endogenously produced substances out of which tachykinins can be important. It is thus possible that these endogenously produced substances have a previously unrecognized importance in mediating effects on muscle tissue in situations with pronounced overuse. It remains for future studies to reveal if blocking of tachykinin effects via use of NK-1 R blocking substances can be of importance in reducing the tissue effects that marked muscle overuse leads to.
The authors are grateful to Ms. Ulla Hedlund for excellent technical assistance at the laboratory, and to Mr. Adrian Lamouroux and Ms. Fellon Robson-Long for excellent technical service concerning the animal model. The Faculty of Medicine, Umeå University, the Swedish National Centre for Research in Sports (CIF), and the J.C. Kempe and Seth M. Kempe Memorial Foundations supported the study. A stipend had been given from the China Scholarsip Council. A stipend had also been given from Margarata, Kjell och Håkan Alfredsons Stiftelse. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. There is no actual or potential conflict of interest including financial, personal or other relationships with other people or organizations.
- Tews DS, Goebel HH: Cytokine expression profile in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol. 1996, 55: 342-347. 10.1097/00005072-199603000-00009.View ArticlePubMedGoogle Scholar
- De Bleeker JL, Meire VI, Declerq W, Van Aken EH: Immunolocalization of tumor necrosis-factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord. 1999, 9: 239-246. 10.1016/S0960-8966(98)00126-6.View ArticleGoogle Scholar
- Fedorczyk JM, Barr AE, Rani S, Gao HG, Amin M, Amin S, Litvin J, Barbe MF: Exposure-dependent increases in IL-1beta, substance P, CTGF, and tendinosis in flexor digitorum tendons with upper extremity repetitive strain injury. J Orthop Res. 2010, 28: 298-307.PubMedPubMed CentralGoogle Scholar
- Song Y, Forsgren S, Yu J, Lorentzon R, Stål P: Effects on contralateral muscles after unilateral electrical muscle stimulation and exercise. PLoS One. 2012, 7 (12): e52230-10.1371/journal.pone.0052230.View ArticlePubMedPubMed CentralGoogle Scholar
- Song Y, Stål P, Yu J, Forsgren S: Bilateral increase in expression and concentration of tachykinin in a unilateral rabbit muscle overuse model that leads to myositis. BMC Musculoskel Disord. 2013, 14: 134-10.1186/1471-2474-14-134. doi:10.1186/1471-2474View ArticleGoogle Scholar
- Song Y, Stål P, Yu J, Forsgren S: Marked effects of tachykinin in myositis both in the experimental side and contralaterally – Studies on NK-1 receptor expressions in an animal model. ISRN Inflamm. 2013, ᅟ: ᅟ-doi.org/10.1155/907821Google Scholar
- Otsuka M, Yoshioka K: Neurotransmitter functions of mammalian tachykinins. Physiol Rev. 1993, 73: 229-308.PubMedGoogle Scholar
- Harrison S, Geppetti P: Substance P. Review. Int J Biochem Cell Biol. 2001, 33: 555-576. 10.1016/S1357-2725(01)00031-0.View ArticlePubMedGoogle Scholar
- O’Connor TM, O’Connell J, O'Brien DI, Goode T, Bredin CP, Shanahan F: The role of substance P in inflammatory disease. J Cell Physiol. 2004, 201: 167-180. 10.1002/jcp.20061.View ArticlePubMedGoogle Scholar
- Renzi D, Pellegrini B, Tonelli F, Surrenti C, Calabro A: Substance P (neurokinin-1) and neurokinin A (neurokinin-2) receptor gene and protein expression in the healthy and inflamed human intestine. Am J Pathol. 2000, 157: 1511-1522. 10.1016/S0002-9440(10)64789-X.View ArticlePubMedPubMed CentralGoogle Scholar
- Costa SKP, Moreno RA, Esquisatto LCM, Juliano L, Brain SD, De Nucci G, Antunes E: Role of kinins and sensory neurons in the rat pleural leukocyte migration induced by Phoneutria nigriventer Spider Venom. Neurosci Lett. 2002, 318: 158-162. 10.1016/S0304-3940(01)02498-3.View ArticlePubMedGoogle Scholar
- Luger TA: Neuromediators – a cricial component of the skin immune system. J Dermatol Sci. 2002, 30: 87-93. 10.1016/S0923-1811(02)00103-2.View ArticlePubMedGoogle Scholar
- Mantelli F, Micera A, Sacchetti M, Bonini S: Neurogenic inflammation of the ocular surface. Curr Opin Allergy Clin Immunol. 2010, 10: 498-504. 10.1097/ACI.0b013e32833e16cc.View ArticlePubMedGoogle Scholar
- Pereira U, Boulais N, Lebonvallet N, Lefeuvre L, Gougerot A, Misery L: Development of an in vitro coculture of primary sensitive pig neurons and keratinocytes for the study of cutaneous neurogenic inflammation. Exp Dermatol. 2010, 19: 931-935. 10.1111/j.1600-0625.2010.01119.x.View ArticlePubMedGoogle Scholar
- Cao T, Pinter E, Al-Rashed S, Gerard N, Hoult JR: Neurokinin-1 receptor agonists are involved in medating neutrophil accumulation in the inflamed, but not normal, cutaneous microvaculature: an in vivo study using neurokinin-1 receptor knockout mice. J Immunol. 2000, 164: 5424-5429.View ArticlePubMedGoogle Scholar
- Li X, Ma G, Ma Q, Li W, Liu J, Han L, Duan W, Xu Q, Liu H, Wang Z, Sun Q, Wang F, Wu E: Neurotransmitter substance P mediates pancreatic cancer perineural invasion via NK-1R in cancer cells. Mol Cancer Res. 2013, ᅟ: 294-302. doi:10.1158/1541-7786View ArticleGoogle Scholar
- Ping F, Shang J, Zhou J, Song J, Zhang L: Activation of neurokinin-1 receptor by substance P inhibits melanogenesis in B16-F10 melanoma cells. Int J Biochem Cell Biol. 2012, 44: 2342-2348. 10.1016/j.biocel.2012.09.025.View ArticlePubMedGoogle Scholar
- Nishida T: Neurotrophic mediators and corneal wound healing. Ocul Surf. 2005, 3: 194-202. 10.1016/S1542-0124(12)70206-9.View ArticlePubMedGoogle Scholar
- Delgado AV, McManus AT, Chambers JP: Exogenous administration of substance P enhances wound healing in a novel skin-injury model. Exp Biol Med. 2005, 230: 271-280.Google Scholar
- Scott JR, Tamura RN, Muangman P, Isik FF, Xie C, Gibran NS: Topical substance P increases inflammatory cell density in genetically diabetic murine wounds. Wound Repair Regen. 2008, 16: 529-533. 10.1111/j.1524-475X.2008.00400.x.View ArticlePubMedPubMed CentralGoogle Scholar
- Carlsson O, Schizas N, Li J, Ackermann PW: Substance P injections enhance tissue proliferation and regulate sensory nerve ingrowth in rat tendon repair. Scand J Med Sci Sports. 2011, 21: 562-569. 10.1111/j.1600-0838.2009.01080.x.View ArticlePubMedGoogle Scholar
- Steyaert A, Burssens P, Forsyth R, Vanderstraeten G: Qualitative analysis of substance P, NK1-receptor and nerve ingrowth in substance P-treated ruptured rat Achilles tendon. Acta Orthop Belg. 2010, 76: 387-395.PubMedGoogle Scholar
- Andersson G, Forsgren S, Scott A, Gaida JE, Stjernfeldt JE, Lorentzon R, Alfredson H, Backman C, Danielson P: Tenocyte hypercellularity and vascular proliferation in a rabbit model of tendinopathy – contralateral effects suggest the involvement of central neuronal mechanisms. Br J Sports Med. 2010, 45: 399-406.View ArticlePubMedGoogle Scholar
- Matsas R, Kenny AJ, Turne AJ: The meatbolism of neuropeptides. The hydrolysis of peptides, including enkephalins, tachykinins, and their analogs, by endopeptidase-24.11. Biochem J. 1984, 223: 433-440.View ArticlePubMedPubMed CentralGoogle Scholar
- Crimi N, Palermo F, Oliveri R, Polosa R, Magri S, Mistreatta A: Inhibition of neutral endopeptidase potentiates bronchoconstriction induced by neurokinin A in asthmatic patients. Clin Exp Allergy. 1994, 24: 115-120. 10.1111/j.1365-2222.1994.tb00206.x.View ArticlePubMedGoogle Scholar
- Mentlein R, Roos T: Proteases involved in the metabolism of angiotensin II, bradykinin, calcitonin gene-related peptide (CGRP), and neuropeptide Y by vascular smooth muscle cells. Peptides. 1996, 17: 709-720. 10.1016/0196-9781(96)00066-6.View ArticlePubMedGoogle Scholar
- Scholzen TE, Luger TA: Neutral endopeptidase and angiotensin-converting enzyme – key enzymes terminating the action of neuroendocrine mediators. Exp Dermatol. 2004, 13: 22-26. 10.1111/j.1600-0625.2004.00260.x.View ArticlePubMedGoogle Scholar
- Backman C, Boquist L, Friden J: Chronic achilles paratenonitis with tendinosis: an experimental model in the rabbit. J Orthop Res. 1990, 8: 541-547. 10.1002/jor.1100080410.View ArticlePubMedGoogle Scholar
- Turner AJ, Tanzawa K: Mammalian membrane metallopeptidases: NEP, ECE, KELL, and PEX. FASEB J. 1997, 11: 355-364.PubMedGoogle Scholar
- Hansson M, Forsgren S: Immunoreactive atrial and brain natriuretic peptides are co-localized in Purkinje fibres but not in the innervation of the bovine heart conduction system. Histochem J. 1995, 27: 222-230. 10.1007/BF02389889.View ArticlePubMedGoogle Scholar
- Gallantini A, Prelle A, Moggio M, Ciscato P, Checcarelli N, Sciacco M, Comini A, Scarlato : Desmin and vimentin as markers of regeneration in muscle diseases. Acta Neuropathol. 1992, 85: 88-92. 10.1007/BF00304637.View ArticleGoogle Scholar
- Young C, Lin MY, Wang PJ, Shen YZ: Immunocytochemical studies on desmin and vimentin in neuromuscular disorders. J Formosa Med Assoc. 1994, 93: 829-835.Google Scholar
- Cuello AC, Galfre G, Milstein C: Development of a monoclonal antibody against a neuroactive peptide: immunocytochemical applications. Adv Biochem Psychopharmacol. 1980, 21: 349-363.PubMedGoogle Scholar
- Lam FF, Yip AL: Unique gradual and sustained vasodilator response to substance P in the rabbit knee joint. Eur J Pharmacol. 2000, 400: 327-335. 10.1016/S0014-2999(00)00400-3.View ArticlePubMedGoogle Scholar
- Skrabanek P, Cannon D, Kirrane J, Legge D, Powell D: Circulating immunoreactive substance P in man. Irish J Med Sci. 1976, 145: 399-408. 10.1007/BF02938979.View ArticlePubMedGoogle Scholar
- Cannon D, Skrabanek P, Powell D: Difference in behaviour between synthetic and endogenous substance P in human plasma. Arch Pharmacol. 1979, 307: 251-255. 10.1007/BF00505941.View ArticleGoogle Scholar
- Lau HY, Wong FL, Bhatia M: A key role of neurokinin 1 receptors in acute pancreatitis and associated lung injury. Biochem Biophys Res Commun. 2005, 327: 509-515. 10.1016/j.bbrc.2004.12.030.View ArticlePubMedGoogle Scholar
- Pinto FM, Ravina CG, Subiran N, Cejudo-Roman A, Fernandez-Sanchez M, Irazusta J, Garrido N, Candenas L: Autocrine regulation of human sperm motility by tachykinins. Reprod Biol Endocrinol. 2010, 8: 104-10.1186/1477-7827-8-104.View ArticlePubMedPubMed CentralGoogle Scholar
- Bring D, Paulson K, Renstrom P, Salo P, Hart D, Ackerman P: Residual substance P levels after capsaicin treatment correlate with tendon repair. Wound Repair Regen. 2012, 20: 50-60. 10.1111/j.1524-475X.2011.00755.x.View ArticlePubMedGoogle Scholar
- Page NM: Hemokinins and endokinins. Cell Mol Life Sci. 2004, 61: 1652-1663.View ArticlePubMedGoogle Scholar
- Renström L, Song Y, Stål P, Forsgren S: TNF-alpha in an overuse muscle model – Relationships to muscle fiber necrosis/regeneration, the NK-1 receptor and an occurrence of bilateral involvement. J Cell Clin Immunol. 2013, ᅟ: ᅟ-In pressGoogle Scholar
- Visayaraghavan J, Scicli AG, Carrettero OA, Slaughter C, Moomaw C, Hersh LB: The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase). J Biol Chem. 1990, 65: 14150-14155.Google Scholar
- Yang H, Erdos EG, Levin Y: A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochem Biophys Acta. 1970, 214: 374-376.PubMedGoogle Scholar
- Jing C, Jia-Han W, Hong-Xing Z: Double-edged effects of neuropeptide substance P on repair of cutaneous trauma. Wound Repair Regen. 2010, 18: 319-324. 10.1111/j.1524-475X.2010.00589.x.View ArticlePubMedGoogle Scholar
- Abdelmagid SM, Barr AE, Rico M, Amin M, Litvin J, Popoff SN, Safadi FF, Barbe MF: Performance of repetitive tasks induces decreased grip strength and increased fibrogenic proteins in skeletal muscle: role of force and inflammation. PloS One. 2012, 7 (5): e38359-10.1371/journal.pone.0038359.View ArticlePubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2474/15/126/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.